Overview
TB-500 is a synthetic peptide corresponding to the 17-amino-acid actin-binding domain of thymosin beta-4 (TB4) — specifically the amino acid sequence LKKTETQ EKLHKLKSEL (residues 17–23 of TB4, sometimes described as positions 1–17 of the active fragment). While the terms "TB-500" and "thymosin beta-4" are often conflated in the functional medicine community, they are technically distinct: thymosin beta-4 is the full 43-amino acid endogenous protein, while TB-500 refers specifically to this synthetic fragment that retains TB4's core biological activity. TB-500 is studied primarily for tissue repair, wound healing, angiogenesis promotion, anti-inflammatory activity, and cardiac repair. Like BPC-157, it is not FDA-approved for any indication, has no completed human RCTs, and is used exclusively off-label via compounded preparations. TB-500 and BPC-157 are frequently co-administered ("the healing peptide stack") based on their complementary mechanisms: BPC-157 primarily drives fibroblast proliferation and VEGF-mediated angiogenesis; TB-500 primarily promotes actin polymerization, cell migration, and anti-inflammatory signaling.
Mechanism of Action
Actin sequestration and cytoskeletal dynamics: Thymosin beta-4 (and TB-500) binds G-actin (monomeric actin) with high affinity, regulating the intracellular pool of actin available for polymerization. By modulating actin dynamics, TB4 governs cell migration, shape changes, and the cytoskeletal reorganization needed for wound healing and tissue remodeling.
Promotion of cell migration: TB4/TB-500 promotes migration of keratinocytes, endothelial cells, and macrophages to injury sites — a prerequisite for wound closure and angiogenesis. This migration effect has been documented in skin wound healing, corneal healing, and cardiac repair models.
Anti-inflammatory modulation: TB-500 downregulates pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while promoting anti-inflammatory mediators including IL-10. This anti-inflammatory profile is distinct from immunosuppression — healing-associated inflammation is preserved while excessive inflammatory signaling is dampened.
Angiogenesis: TB-500 promotes formation of new blood vessels in ischemic and injured tissue via upregulation of VEGF, EGF, and FGF, complementing BPC-157's angiogenic effects through partially overlapping pathways.
Cardiac regeneration: Among the most studied applications of TB4 in academic research is cardiac repair after myocardial infarction. TB4 activates cardiac progenitor cells (Isl1+ cells), promotes cardiomyocyte survival, reduces infarct size, and promotes formation of new capillaries in the peri-infarct zone in murine models. A landmark paper by Smart et al. (Nature, 2007) demonstrated TB4's ability to reactivate dormant epicardial progenitor cells — generating significant interest in TB4 as a cardiac regeneration therapeutic.
Hair growth: TB4/TB-500 promotes differentiation of hair follicle stem cells and was shown to promote hair growth in animal models — generating interest in androgenic alopecia applications.
Tendon and muscle repair: TB-500 promotes satellite cell activation in muscle injury and tenocyte proliferation in tendon injury, accelerating repair in animal models.
Evidence Base
Cardiac repair (animal/preclinical): The most extensively studied academic application. Multiple groups have confirmed TB4 reduces myocardial infarct size, promotes angiogenesis, and activates progenitor cells in rodent MI models. Human Phase I/II trials in acute MI patients (the PILOT-MI and PHASTER trials) were conducted in Europe using IV TB4 — early safety data appeared acceptable but enrollment and outcomes data are not widely published.
Wound healing: TB4 accelerates dermal wound closure in diabetic mice models, corneal wound healing in various models, and anastomosis healing. Thymosin beta-4 eyedrops (RegeneRx, clinical stage) showed benefit in corneal epithelial wound healing in Phase II trials.
Musculoskeletal healing: Animal studies demonstrate accelerated Achilles tendon repair, muscle regeneration, and bone healing with TB4/TB-500. Tendon healing findings parallel BPC-157 studies.
Neurological: TB4 reduces brain edema and improves functional recovery after traumatic brain injury in animal models; promotes oligodendrocyte differentiation and remyelination in spinal cord injury models.
Human evidence: No completed human RCTs for any of the musculoskeletal or anti-aging applications. RegeneRx held IP rights for TB4 pharmaceutical development; their corneal wound healing data represents the closest published human efficacy evidence.
Dosing & Timing
All human dosing is off-label.
| Application | Dose | Route | Notes |
|---|---|---|---|
| Musculoskeletal healing | 2–5 mg twice weekly | SQ injection | 4–8 week cycle |
| Chronic injury / tissue repair | 5 mg once weekly | SQ injection | Maintenance dosing |
| Combined with BPC-157 | BPC-157 250–500 mcg/day + TB-500 2–5 mg 2×/week | SQ | "Healing stack"; complementary mechanisms |
| Acute injury (loading) | 5 mg 2×/week for 4 weeks | SQ | Higher loading dose, then taper |
Reconstitution: Lyophilized powder; reconstitute with bacteriostatic water. Store at 4°C; stable ~28 days.
Forms & Bioavailability
TB-500 is available as lyophilized powder for SQ reconstitution. Bioavailability data in humans is unavailable. Subcutaneous injection is the primary administration route; some practitioners use intramuscular injection.
FDA/regulatory status: Similar to BPC-157 — FDA placed TB4/TB-500 on restricted compounding lists (2023/2024). Verify current legal status before prescribing or obtaining.
Safety & Side Effects
Animal safety: No significant toxicity in preclinical models up to very high doses.
Human reports (observational): Mild fatigue, transient headache, injection site reactions reported. No serious adverse events documented in the functional medicine community at typical doses. The PILOT-MI cardiac trial safety data (IV dosing) was acceptable.
Theoretical cancer concern: TB4 promotes cell migration and angiogenesis — theoretical risk of promoting tumor angiogenesis or metastasis in individuals with active or occult malignancy.
Contraindications (theoretical): Active cancer; pregnancy.
Drug & Supplement Interactions
| Agent | Interaction | Management |
|---|---|---|
| BPC-157 | Complementary mechanisms; commonly combined | Standard clinical combination; monitor for additive effects |
| GH secretagogues | Potentially additive anabolic/healing effects | Common advanced peptide stack |
| NSAIDs | TB-500 may reduce inflammation via different pathway; NSAIDs may interfere with some healing responses | Timing considerations; discuss with physician |
| Anticoagulants | Theoretical concern with angiogenesis promotion | Monitor coagulation parameters |
Who Should Consider It
- Athletes and active individuals with tendon, ligament, or muscle injuries
- Post-surgical patients seeking accelerated wound healing
- Individuals with chronic musculoskeletal pain and poor healing response
- Those interested in cardiovascular repair protocols (under physician/cardiologist supervision)
- Patients considering BPC-157 who want complementary healing peptide coverage
Bottom Line
TB-500 mirrors BPC-157 in having strong, diverse animal data but almost no human trial confirmation and unresolved regulatory status (FDA has restricted compounding of both). The TB4 cardiac regeneration work is scientifically exciting but not ready for clinical prime time. For the more common applications—tendon healing, muscle recovery, wound healing—the animal data is consistent and the combination with BPC-157 is rational based on complementary mechanisms. Any use should be regarded as experimental with special caution in cancer-risk populations, given the theoretical risk that enhanced angiogenesis and cell migration could support tumor growth.
Last reviewed: 2026.